KR101057102B1 - 캄프토테신의 고분자량 유도체 - Google Patents

캄프토테신의 고분자량 유도체 Download PDF

Info

Publication number
KR101057102B1
KR101057102B1 KR1020057007500A KR20057007500A KR101057102B1 KR 101057102 B1 KR101057102 B1 KR 101057102B1 KR 1020057007500 A KR1020057007500 A KR 1020057007500A KR 20057007500 A KR20057007500 A KR 20057007500A KR 101057102 B1 KR101057102 B1 KR 101057102B1
Authority
KR
South Korea
Prior art keywords
group
camptothecin
molecular weight
high molecular
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057007500A
Other languages
English (en)
Korean (ko)
Other versions
KR20050070103A (ko
Inventor
마사유키 키타가와
카쥬야 오카모토
Original Assignee
니폰 가야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니폰 가야꾸 가부시끼가이샤 filed Critical 니폰 가야꾸 가부시끼가이샤
Publication of KR20050070103A publication Critical patent/KR20050070103A/ko
Application granted granted Critical
Publication of KR101057102B1 publication Critical patent/KR101057102B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyamides (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057007500A 2002-10-31 2003-10-29 캄프토테신의 고분자량 유도체 Expired - Fee Related KR101057102B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2002-00316942 2002-10-31
JP2002316942 2002-10-31
PCT/JP2003/013838 WO2004039869A1 (ja) 2002-10-31 2003-10-29 カンプトテシン類の高分子誘導体

Publications (2)

Publication Number Publication Date
KR20050070103A KR20050070103A (ko) 2005-07-05
KR101057102B1 true KR101057102B1 (ko) 2011-08-16

Family

ID=32211705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057007500A Expired - Fee Related KR101057102B1 (ko) 2002-10-31 2003-10-29 캄프토테신의 고분자량 유도체

Country Status (13)

Country Link
US (1) US7495099B2 (https=)
EP (1) EP1580216B1 (https=)
JP (1) JP4745664B2 (https=)
KR (1) KR101057102B1 (https=)
CN (1) CN1309763C (https=)
AU (1) AU2003280592B2 (https=)
CA (1) CA2502870C (https=)
DK (1) DK1580216T3 (https=)
ES (1) ES2488841T3 (https=)
PT (1) PT1580216E (https=)
RU (1) RU2315782C2 (https=)
TW (1) TW200418906A (https=)
WO (1) WO2004039869A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475269C (zh) * 2002-03-05 2009-04-08 北京键凯科技有限公司 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途
ES2291620T3 (es) 2002-03-13 2008-03-01 Beijing Jiankai Technology Co., Ltd. Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior.
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
JP4820758B2 (ja) * 2004-09-22 2011-11-24 日本化薬株式会社 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
ATE465205T1 (de) * 2005-12-05 2010-05-15 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
JP5249016B2 (ja) 2006-03-28 2013-07-31 日本化薬株式会社 タキサン類の高分子結合体
KR20090009241A (ko) 2006-05-18 2009-01-22 니폰 가야꾸 가부시끼가이샤 포도필로톡신류의 고분자 결합체
KR20090031597A (ko) 2006-07-19 2009-03-26 니폰 가야꾸 가부시끼가이샤 콤브레타스타틴류의 고분자 결합체
ES2584840T3 (es) * 2006-10-03 2016-09-29 Nippon Kayaku Kabushiki Kaisha Compuesto de un derivado de resorcinol con un polímero
WO2008056596A1 (fr) 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Dérivé polymère d'un antagoniste métabolique d'acide nucléique
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
PT2155255E (pt) 2007-05-09 2013-10-15 Nitto Denko Corp Composições que incluem um composto hidrofóbico e um conjugado de poliaminoácido
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
WO2009116509A1 (ja) 2008-03-18 2009-09-24 日本化薬株式会社 生理活性物質の高分子結合体
WO2009136572A1 (ja) 2008-05-08 2009-11-12 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
JP2011162569A (ja) 2008-05-23 2011-08-25 Nano Career Kk カンプトテシン高分子誘導体及びその用途
DK2287230T3 (da) 2008-05-23 2012-12-10 Nanocarrier Co Ltd Docetaxel polymer derivative, method for producing same and use of same
WO2010083154A2 (en) * 2009-01-13 2010-07-22 The Uab Research Foundation Heterofunctional segment-poly(ethylene glycol) polymers as delivery vehicles
CA2760771A1 (en) * 2009-05-04 2010-11-11 Intezyne Technologies, Incorporated Polymer micelles containing sn-38 for the treatment of cancer
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
US20120231053A1 (en) * 2009-10-21 2012-09-13 Nippon Kayaku Kabushiki Kaisha Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient
JP2011225510A (ja) * 2010-04-01 2011-11-10 National Cancer Center 新規な抗腫瘍剤
EP2641605B1 (en) 2010-11-17 2018-03-07 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolism antagonist
KR101849142B1 (ko) 2011-09-11 2018-04-16 니폰 가야꾸 가부시끼가이샤 블록 공중합체의 제조방법
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014073447A1 (ja) 2012-11-08 2014-05-15 日本化薬株式会社 カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
DK3052101T3 (da) 2013-10-04 2019-12-16 Prolynx Llc Konjugater af sn-38 med langsom frigivelse
JP6580030B2 (ja) * 2014-02-19 2019-09-25 日本化薬株式会社 カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途
WO2015125641A1 (ja) * 2014-02-19 2015-08-27 日本化薬株式会社 高分子化カンプトテシン誘導体及び高分子化ｈｓｐ９０阻害剤誘導体を含む医薬組成物
JP2016124818A (ja) * 2014-12-26 2016-07-11 日本化薬株式会社 転移性肝癌治療薬及び転移性肝癌の治療方法
CA2969196C (en) * 2014-12-26 2021-04-13 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
RU2732612C2 (ru) * 2015-02-23 2020-09-21 Ниппон Каяку Кабусики Каися Блок-сополимерный конъюгат физиологически активного вещества
EP3315487B1 (en) 2015-06-24 2020-10-28 Nippon Kayaku Kabushiki Kaisha Novel platinum (iv) complex
CA2995053A1 (en) 2015-09-03 2017-03-09 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition containing camptothecin polymer derivative
AU2016324370B2 (en) 2015-09-14 2021-02-25 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of hexa-coordinated platinum complex
US11026889B2 (en) * 2015-12-09 2021-06-08 Board Of Regents, The University Of Texas System Polymeric drug delivery systems for treatment of disease
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
RU2721725C2 (ru) 2015-12-22 2020-05-21 Ниппон Каяку Кабусики Каися Полимерный конъюгат координационного комплекса платины (ii) с производным сульфоксида
JP6797182B2 (ja) * 2016-03-01 2020-12-09 日本化薬株式会社 カンプトテシン類高分子誘導体を含有する医薬製剤
CN109476841B (zh) 2016-07-30 2021-08-24 日本化药株式会社 新型高分子衍生物和使用其的新型高分子衍生物成像探针
JPWO2018025699A1 (ja) 2016-08-02 2019-05-30 日本化薬株式会社 アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途
CN106496542B (zh) * 2016-09-23 2018-06-22 天津科技大学 谷胱甘肽敏感的两亲性聚乙二醇-羟基喜树碱偶联物
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
JP7187048B2 (ja) 2017-06-30 2022-12-12 マサチューセッツ インスティテュート オブ テクノロジー 分枝多官能性マクロモノマーおよび関連ポリマーならびにそれらの使用
MX2020007306A (es) 2018-01-12 2020-09-25 Prolynx Llc Tratamiento sinergico de cancer.
EP3837266A1 (en) 2018-08-17 2021-06-23 Massachusetts Institute of Technology Degradable polymers of a cyclic silyl ether and uses thereof
AU2020278465B2 (en) 2019-05-20 2026-04-23 Dana-Farber Cancer Institute, Inc. Boronic ester prodrugs and uses thereof
WO2021141662A1 (en) 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839683A (ja) * 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPH05117385A (ja) * 1991-10-31 1993-05-14 Res Dev Corp Of Japan ブロツク共重合体の製造法、ブロツク共重合体及び水溶性高分子抗癌剤
KR20020082888A (ko) * 2000-03-17 2002-10-31 쎌세러퓨틱스,인코포레이티드 폴리글루탐산-캄프토테신 컨주게이트 및 제조 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6247193A (ja) 1985-08-26 1987-02-28 内橋エステック株式会社 電子部品のはんだ付方法
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
JP3310000B2 (ja) 1990-11-07 2002-07-29 靖久 桜井 水溶性高分子抗癌剤及び薬物担持用担体
JP3270592B2 (ja) * 1992-10-26 2002-04-02 日本化薬株式会社 ブロック共重合体−抗癌剤複合体医薬製剤
JP3268913B2 (ja) 1992-10-27 2002-03-25 日本化薬株式会社 高分子担体
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
FR2757515B1 (fr) * 1996-12-20 2000-05-05 Sod Conseils Rech Applic Formes prodrogues et nouveaux analogues de la camptothecine, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JP2694923B2 (ja) 1995-08-21 1997-12-24 科学技術振興事業団 水溶性高分子化医薬製剤
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6207832B1 (en) * 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
ATE541587T1 (de) 2000-06-02 2012-02-15 Eidgenoess Tech Hochschule Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
EP1408066B1 (en) * 2001-06-20 2010-03-31 Nippon Kayaku Kabushiki Kaisha Block copolymer reduced in impurity content; polymeric carrier; pharmaceutical preparations in polymeric form and process for the preparation of the same
JP2003342168A (ja) * 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
JP2003342167A (ja) * 2002-05-24 2003-12-03 Nano Career Kk カンプトテシン誘導体の製剤およびその調製方法
EP1594482A1 (en) * 2003-03-26 2005-11-16 LTT Bio-Pharma Co., Ltd. Intravenous nanoparticles for targeting drug delivery and sustained drug release
KR101312417B1 (ko) * 2005-05-11 2013-09-27 니폰 가야꾸 가부시끼가이샤 시티딘계 대사길항제의 고분자 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839683A (ja) * 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPH05117385A (ja) * 1991-10-31 1993-05-14 Res Dev Corp Of Japan ブロツク共重合体の製造法、ブロツク共重合体及び水溶性高分子抗癌剤
KR20020082888A (ko) * 2000-03-17 2002-10-31 쎌세러퓨틱스,인코포레이티드 폴리글루탐산-캄프토테신 컨주게이트 및 제조 방법

Also Published As

Publication number Publication date
RU2005116309A (ru) 2006-02-27
JPWO2004039869A1 (ja) 2006-03-02
US7495099B2 (en) 2009-02-24
AU2003280592A1 (en) 2004-05-25
WO2004039869A1 (ja) 2004-05-13
EP1580216A1 (en) 2005-09-28
TWI305538B (https=) 2009-01-21
CA2502870A1 (en) 2004-05-13
RU2315782C2 (ru) 2008-01-27
EP1580216A4 (en) 2008-10-29
TW200418906A (en) 2004-10-01
PT1580216E (pt) 2014-07-31
AU2003280592B2 (en) 2008-12-18
EP1580216B1 (en) 2014-05-14
JP4745664B2 (ja) 2011-08-10
KR20050070103A (ko) 2005-07-05
CN1309763C (zh) 2007-04-11
ES2488841T3 (es) 2014-08-29
US20060067910A1 (en) 2006-03-30
CN1708540A (zh) 2005-12-14
DK1580216T3 (da) 2014-08-18
CA2502870C (en) 2011-07-26

Similar Documents

Publication Publication Date Title
KR101057102B1 (ko) 캄프토테신의 고분자량 유도체
US8323669B2 (en) Polymer conjugate of taxane
JP5008783B2 (ja) 高分子量のポリマーを基剤とするプロドラッグ
EP2258397B1 (en) Polymer conjugate of physiologically active substance
US8940332B2 (en) High-molecular weight conjugate of podophyllotoxins
EP2042195A1 (en) Polymer conjugate of combretastatin
USRE46190E1 (en) High-molecular weight conjugate of steroids
EP0807115A4 (en) MEDICAMENTS BASED ON POLYMERS WITH HIGH MOLECULAR WEIGHT
JP6223995B2 (ja) カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20140508

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20150716

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20160720

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20170719

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20180718

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20190718

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200810

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200810